Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Sandhya Mudumbi

Hospice and Palliative Medicine Nashville, TN Medical Doctor

NPI 1902249089 CMS profile 2833909

2004 Hayes St Ste 350, Nashville, TN 37203

Open in the dashboard

General payments

$1,575

50 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sandhya Mudumbi of Nashville, TN is reported in the CMS Open Payments database as having received $1,575 across 50 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Hospice and Palliative Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $164 6
2024 General $461 19
2023 General $449 18
2022 General $285 5
2020 General $215 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sandhya Mudumbi
  • Hospice and Palliative Medicine median
  • Middle half of Hospice and Palliative Medicine
  • National median

In program year 2025, general payments to Sandhya Mudumbi were reported at $164. Among 378 Hospice and Palliative Medicine profiles paid that year, the median was $78 and the middle half received between $28 and $160.

Show as a table
Year Sandhya Mudumbi Hospice and Palliative Medicine median Middle half National median
2019 $0 $80 $22–$147 $163
2020 $215 $36 $18–$121 $114
2021 $0 $64 $23–$194 $132
2022 $285 $67 $22–$158 $149
2023 $449 $65 $25–$149 $160
2024 $461 $75 $25–$158 $164
2025 $164 $78 $28–$160 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Lilly USA, LLC $459 5 payments
  2. AstraZeneca Pharmaceuticals LP $215 9 payments
  3. Regeneron Healthcare Solutions, Inc. $133 4 payments
  4. Aveo Pharmaceuticals, Inc. $121 3 payments
  5. Merck Sharp & Dohme Corporation $106 4 payments
  6. Eisai Inc. $93 4 payments
  7. Janssen Biotech, Inc. $66 3 payments
  8. Exelixis Inc. $54 2 payments
  9. AbbVie, Inc. $47 2 payments
  10. Novartis Pharmaceuticals Corporation $39 2 payments
  11. Other $242 12 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $1,210 47 payments
  2. Education $365 3 payments
Products named General payments · program years 2020–2025
  1. VERZENIO $202 3 payments
  2. LIBTAYO $133 4 payments
  3. FOTIVDA $121 3 payments
  4. RETEVMO $108 1 payment
  5. CYRAMZA $108 1 payment
  6. ALIMTA $108 1 payment
  7. KEYTRUDA $106 4 payments
  8. CALQUENCE $101 4 payments
  9. Lenvima $93 4 payments
  10. WELIREG $49 2 payments
  11. Other $590 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

734

Median for Hospice and Palliative Care: 260

Drug cost

$66,895

Median for Hospice and Palliative Care: $10,445

Branded share of claims

33.2%

Median for Hospice and Palliative Care: 16.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 30 $37,198
Xtampza Er Oxycodone Myristate Brand 25 $16,418
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 108 $3,532
Oxycodone Hcl Generic 132 $2,452
Fentanyl Generic 37 $2,148
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 13 $628
Morphine Sulfate Er Morphine Sulfate Brand 29 $586
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 24 $574
Quetiapine Fumarate Generic 39 $560
Duloxetine Hcl Generic 40 $470

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,124 Part D prescribers listed as Hospice and Palliative Care; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$29,484

Medicare's payments for the services billed

Medicare patients

48

Average age 72

Services billed

718

33 women, 15 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Cancer 67%
Arthritis 46%
Depression 44%
Chronic kidney disease 40%
Diabetes 38%
COPD 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FOTIVDA
  • Aveo Pharmaceuticals, Inc. $80
$80 — —
LIBTAYO
  • Regeneron Healthcare Solutions, Inc. $65
$65 — —
VENCLEXTA
  • AbbVie, Inc. $47
$47 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $40
$40 — —
PLUVICTO
  • Novartis Pharmaceuticals Corporation $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

50 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hospice and Palliative Medicine in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record